The treatment of haematologic neoplasms has been, in recent years, one of the areas of oncology that has experienced the most significant improvement in clinical outcomes, both in the effective control of the progression of the disease, as well as in increased overall survival rates. Our Haemato-Oncology team consists of medical specialists with a strong interest and prior experience in laboratory research of lymphoproliferative diseases and multiple myeloma. The objective of the unit is the introduction of innovative treatments through multi-centre cooperative clinical trials, or medicines which have already been approved but not yet marketed, through early access programmes.
Our Haemato-Oncology Unit doctors
Paulo Lúcio, Director of the Haemato-Oncology Unit